|
[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.
|
|
[2]REVIEW T, ZAIGHAM A, FRANK A, et al.World Gastroenterology Organisation global guidelines:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].J Clin Gastroenterol, 2014, 48 (6) :467-473.
|
|
[3]SINGAL A, MANJUNATH H, YOPP AC, et al.The effect of PNPLA3 on fibrosis progression and development of hepato-cellular carcinoma:A meta-analysis[J].Am J Gastroenterol, 2014, 109:325-334.
|
|
[4]JIANG LN, ZHAO JM.The role of liver histology in the clinical study and practice of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (12) :2303-2306. (in Chinese) 蒋丽娜, 赵景民.肝组织学评估在非酒精性脂肪性肝病临床研究及实践中的作用[J].临床肝胆病杂志, 2017, 33 (12) :2303-2306.
|
|
[5]YOSHIO S, ATSUSHI N, YOSHITO I, et al.Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World JGastroenterol, 2014, 20 (2) :475-485.
|
|
[6]WATANABE S, HASHIMOTO E, IKEJIMA K, et al.Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease nonalcoholic steatohepatitis[J].J Gastroenterol, 2015, 50 (4) :364-377.
|
|
[7]EDUARDO V, NAGA C.Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers[J].J Hepatol, 2018, 68 (2) :305-315.
|
|
[8]PETTA S, WONG VW, CAMMC, et al.Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD[J].Aliment Pharmacol Ther, 2017, 46 (6) :617-627.
|
|
[9]SUMIDA Y, YONEDA M, HYOGO H, et al.Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population[J].BMC Gastroenterol, 2012, 12:2.
|
|
[10]Mc PHERSON S, STEWART SF, HENDERSON E, et al.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J].Gut, 2010, 59 (9) :1265-1269.
|
|
[11]GIULIO M, JEAN F, ALI C et al, European Association for the Study of the Liver (EASL) ;European Association for the Study of Diabetes (EASD) ;European Association for the Study of Obesity (EASO) .EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J].Obes Facts, 2016, 9 (2) :65-90.
|
|
[12]JUAN PA, CRISTIAN HR, CAROLINA M, et al.Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population[J].Gastroenterol Hepatol, 2017, 40 (6) :388-394.
|
|
[13]MANDELIA C, COLLYER E, MANSOOR S, et al.Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease[J].J Pediatr Gastroenterol Nutr, 2016, 63 (2) :167-168.
|
|
[14]CUSI K, CHANG Z, HARRISON S, et al.Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease[J].J Hepatol, 2014, 60 (1) :167-174.
|
|
[15]BI Y, MIN M, SHEN W, et al.Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease[J].Int J Clin Exp Pathol, 2015, 8 (7) :8494-8499.
|
|
[16]YONEDA M, MAWATARI H, FUJITA K, et al.High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH[J].J Gastroenterol, 2007, 42 (7) :573-582.
|
|
[17]MALEKI I, RASTGAR A, HOSSEINI V, et al.High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease[J].Eur Rev Med Pharmacol Sci, 2014, 18 (11) :1583-1590.
|
|
[18]LEE J, YOON K, RYU S, et al.High-normal levels of hs-CRPpredict the development of non-alcoholic fatty liver in healthy men[J].PLo S One, 2017, 12 (2) :e0172666.
|
|
[19]MIELE L, de MICHELE T, MARRONE G, et al.Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting[J].Int J Biol Markers, 2017, 32 (4) :e397-e402.
|
|
[20]YOSHIO S, MASATO Y, HIDEYUKI H, et al.A simple clinical scoring system using ferritin, fasting insulin, and typeⅣcollagen 7Sfor predicting steatohepatitis in nonalcoholic fatty liver disease[J].J Gastroenterol, 2011, 46 (2) :257-268.
|
|
[21]TADA T, KUMADA T, TOYODA H, et al.New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease[J].Biomarkers, 2018, 23 (4) :328-334.
|
|
[22]TAKESHI O, HAYAO E, TOSHIHIRO K, et al.A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis[J].JGastroenterol, 2018, 53 (1) :129-139.
|
|
[23]YOSHIHIRO K, MASAFUMI O, HIDEYUKI H, et al.A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers[J].Hepatology, 2015, 62 (5) :1433-1443.
|
DownLoad: